Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 1569189.
- Also identified by PMC identifier 443023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. This oncogene, papillary thyroid carcinoma (PTC), is a novel rearranged version of the ret tyrosine-kinase protooncogene. Thyroid neoplasms include a broad spectrum of malignant tumors, ranging from well-differentiated tumors to undifferentiated anaplastic carcinomas. To determine the frequency of ret oncogene activation, we analyzed 286 cases of human thyroid tumors of diverse histologic types. We found the presence of an activated form of the ret oncogene in 33 (19%) of 177 papillary carcinomas. By contrast, none of the other 109 thyroid tumors, which included 37 follicular, 15 anaplastic, and 18 medullary carcinomas, and 34 benign lesions, showed ret activation.
Medical subject headings
- Carcinoma, Papillary
- Drosophila Proteins
- Oncogenes
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases
- Thyroid Neoplasms